We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
(+27%)
Cap. Flow
+$9.92M
Cap. Flow
% of AUM
0.69%
Top 10 Holdings %
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55
Avg Time Held Equity + Options
2.9
quarters
Top 10 Avg Time Held Equity + Options
4.7
quarters
Top 20 Avg Time Held Equity + Options
4.1
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
4.7
quarters
Top 20 Avg Time Held Equity only
4.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXTM
NxStage Medical Inc.
NXTM
|
+$24.7M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$23.8M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$18.4M |
| 4 |
STJ
St Jude Medical
STJ
|
+$16.6M |
| 5 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
+$11.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$41.5M |
| 2 |
Humana
HUM
|
+$20.1M |
| 3 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
+$12.4M |
| 4 |
Baxter International
BAX
|
+$9.04M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$6.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.68% |
| 2 | Miscellaneous | 20.64% |
| 3 | Consumer Staples | 0.52% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
176
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-51,200
| Closed | -$60K | – |
|
177
Curis
CRIS
$1.49M
| – | – |
-50
| Closed | -$161K | – |
|
178
Enanta Pharmaceuticals
ENTA
$336M
| – | – |
-17,507
| Closed | -$514K | – |
|
179
DELISTED
Fonar
FONR
| – | – |
-8,473
| Closed | -$130K | – |
|
180
Gilead Sciences
GILD
$183B
| – | – |
-6,024
| Closed | -$553K | – |
|
181
Eocene Ltd. Ordinary Shares
EOCN
$3.39M
| – | – |
-52
| Closed | -$369K | – |
|
182
DELISTED
Hologic
HOLX
| – | – |
-14,732
| Closed | -$508K | – |
|
|
183
Humana
HUM
$50.5B
| – | – |
-110,000
| Closed | -$20.1M | – |
|
184
Icon
ICLR
$12.7B
| – | – |
-7,585
| Closed | -$570K | – |
|
185
Immunic
IMUX
$94M
| – | – |
-75
| Closed | -$271K | – |
|
186
Indaptus Therapeutics
INDP
$318M
| – | – |
-86
| Closed | -$795K | – |
|
187
IQVIA
IQV
$42.9B
| – | – |
-7,447
| Closed | -$485K | – |
|
188
Myriad Genetics
MYGN
$390M
| – | – |
-3,333
| Closed | -$125K | – |
|
189
Neurogene
NGNE
$431M
| – | – |
-2,980
| Closed | -$526K | – |
|
190
Novo Nordisk
NVO
$168B
| – | – |
-233,320
| Closed | -$6.32M | – |
|
191
Omeros
OMER
$1.37B
| – | – |
-200,000
| Closed | -$3.07M | – |
|
192
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-2,712
| Closed | -$2.26M | – |
|
193
State Street SPDR S&P 500 ETF Trust
SPY
$822B
| – | – |
-1,600
| Closed | -$329K | – |
|
194
Tandem Diabetes Care
TNDM
$1.16B
| – | – |
-2,500
| Closed | -$217K | – |
|
195
DELISTED
Titan Pharmaceuticals
TTNP
| – | – |
0
| – | – |
2016 Q2
0 quarters
|
|
196
Vanda Pharmaceuticals
VNDA
$260M
| – | – |
-71,849
| Closed | -$601K | – |
|
197
DELISTED
Walgreens Boots Alliance
WBA
| – | – |
-35,292
| Closed | -$2.97M | – |
|
198
Zimmer Biomet
ZBH
$17.6B
| – | – |
-161
| Closed | -$17K | – |
|
199
CALL
DELISTED
NEVRO CORP.
NVRO
| – | – |
-100,000
| Closed | -$5.63M | – |
|
200
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| – | – |
-3,429
| Closed | -$491K | – |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2016 Portfolio in Review
As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors's Q2 2016 filing shows 57 new, 37 increased, 31 reduced and 55 closed positions. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M. The largest sale was Allergan plc, an estimated $41.5M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
- Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
- Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
- Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
- Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
- Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
- Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.
Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.